Literature DB >> 499229

Iodine 131 labelled ioglycamic acid (Biligram) for scintiscanning in hepatobiliary disorders.

J N Blackwell, N D Finlayson, G P McLoughlin, M D Sumerling, P Tothill.   

Abstract

Iodine-131 labelled Biligram has been evaluated as a radiopharmaceutical for dynamic scintiscanning of the liver and biliary tract. In 10 normal subjects there was good visualisation of the liver and gallbladder. In 18 patients 131I Biligram was found to be unsatifactory for differentiating parenchymal liver disease from biliary tract obstruction owing to inability to demonstrate the gallbladder when liver function was more than mildly deranged. Quantitative analyses of blood clearance and hepatic activity curves for 131I Biligram were not clinically helpful. Urinary excretion of 131I Biligram increased with the degree of hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499229     DOI: 10.1007/bf00257562

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  Evaluation of the radioactive (I 131-tagged) rose bengal liver function test in nonjaundiced patients.

Authors:  C G MOERTEL; C A OWEN
Journal:  J Lab Clin Med       Date:  1958-12

2.  An evaluation of 99mTc-labeled hepatobiliary agents.

Authors:  B W Wistow; G Subramanian; R L Heertum; R W Henderson; G M Gagne; R C Hall; J G McAfee
Journal:  J Nucl Med       Date:  1977-05       Impact factor: 10.057

3.  123I-iodo-bromsulphalein as a liver and biliary scanning agent.

Authors:  M L Goris
Journal:  J Nucl Med       Date:  1973-11       Impact factor: 10.057

4.  131 I rose bengal imaging techniques in differential diagnosis of jaundiced patients.

Authors:  M A Winston; W H Blahd
Journal:  Semin Nucl Med       Date:  1972-04       Impact factor: 4.446

5.  Contrast-protein interactions.

Authors:  E C Lasser; J H Lang
Journal:  Invest Radiol       Date:  1970 Nov-Dec       Impact factor: 6.016

6.  Compartmental analysis of sulfobromophthalein transport in normal patients and patients with hepatic dysfunction.

Authors:  S H Quarfordt; H L Hilderman; D Valle; E Waddell
Journal:  Gastroenterology       Date:  1971-02       Impact factor: 22.682

7.  Hepatobiliary radiopharmaceuticals: defining their clinical role will be a galling experience.

Authors:  P M Ronai
Journal:  J Nucl Med       Date:  1977-05       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.